Company’s 36-month beta value is 1.29.Analysts have differing opinions on the stock, with 7 analysts rating it as a “buy,” 6 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for DYN is 87.33M, and currently, short sellers hold a 12.99% ratio of that floaft. The average trading volume of DYN on April 17, 2025 was 2.25M shares.
DYN) stock’s latest price update
Dyne Therapeutics Inc (NASDAQ: DYN) has experienced a decline in its stock price by -0.25 compared to its previous closing price of 7.85. However, the company has seen a gain of 3.71% in its stock price over the last five trading days. globenewswire.com reported 2025-04-15 that – Vikram Ranade, PhD, appointed as chief business officer – – Ranjan Batra, PhD, appointed as chief scientific officer – – Oxana Beskrovnaya, PhD, transitioning to chief innovation officer – WALTHAM, Mass., April 15, 2025 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced the appointments of Vikram (Vik) Ranade, PhD, as chief business officer (CBO) and Ranjan (Ron) Batra, PhD, as chief scientific officer (CSO) of Dyne.
DYN’s Market Performance
DYN’s stock has risen by 3.71% in the past week, with a monthly drop of -37.76% and a quarterly drop of -49.61%. The volatility ratio for the week is 7.90% while the volatility levels for the last 30 days are 9.84% for Dyne Therapeutics Inc The simple moving average for the last 20 days is -17.13% for DYN’s stock, with a simple moving average of -70.97% for the last 200 days.
Analysts’ Opinion of DYN
Many brokerage firms have already submitted their reports for DYN stocks, with BMO Capital Markets repeating the rating for DYN by listing it as a “Outperform.” The predicted price for DYN in the upcoming period, according to BMO Capital Markets is $50 based on the research report published on March 12, 2025 of the current year 2025.
Scotiabank, on the other hand, stated in their research note that they expect to see DYN reach a price target of $50. The rating they have provided for DYN stocks is “Sector Outperform” according to the report published on March 07th, 2025.
Robert W. Baird gave a rating of “Outperform” to DYN, setting the target price at $46 in the report published on December 13th of the previous year.
DYN Trading at -33.43% from the 50-Day Moving Average
After a stumble in the market that brought DYN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.50% of loss for the given period.
Volatility was left at 9.84%, however, over the last 30 days, the volatility rate increased by 7.90%, as shares sank -36.85% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -47.06% lower at present.
During the last 5 trading sessions, DYN rose by +3.71%, which changed the moving average for the period of 200-days by -77.81% in comparison to the 20-day moving average, which settled at $9.45. In addition, Dyne Therapeutics Inc saw -66.77% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DYN starting from Friedl-Naderer Johanna, who sale 143 shares at the price of $12.12 back on Mar 13 ’25. After this action, Friedl-Naderer Johanna now owns 96,057 shares of Dyne Therapeutics Inc, valued at $1,733 using the latest closing price.
Scalzo Richard William, the SVP, Head of Finance & Admin. of Dyne Therapeutics Inc, sale 1,343 shares at $11.38 during a trade that took place back on Mar 11 ’25, which means that Scalzo Richard William is holding 122,330 shares at $15,283 based on the most recent closing price.
Stock Fundamentals for DYN
The total capital return value is set at -0.53. Equity return is now at value -88.03, with -74.14 for asset returns.
Based on Dyne Therapeutics Inc (DYN), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -12.19.
Currently, EBITDA for the company is -343.89 million with net debt to EBITDA at 1.2. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.60.
Conclusion
In a nutshell, Dyne Therapeutics Inc (DYN) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
